Indian Journal of Medical Microbiology IAMM  | About us |  Subscription |  e-Alerts  | Feedback |  Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Ahead of Print | Current Issue | Archives | Search | Instructions  
Users Online: 1023 Official Publication of Indian Association of Medical Microbiologists 
  Search
 
  
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~  Article in PDF (479 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

 
 ~  References

 Article Access Statistics
    Viewed88    
    Printed0    
    Emailed0    
    PDF Downloaded24    
    Comments [Add]    

Recommend this journal

 


 
  Table of Contents  
CORRESPONDENCE
Year : 2017  |  Volume : 35  |  Issue : 1  |  Page : 143-145
 

Introducing rubella vaccine into the national immunisation schedule


Professor, Pediatric Infectious Diseases, Department of Paediatrics, Christian Medical College, Vellore, Tamil Nadu, India

Date of Web Publication16-Mar-2017

Correspondence Address:
Valsan Philip Verghese
Professor, Pediatric Infectious Diseases, Department of Paediatrics, Christian Medical College, Vellore, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmm.IJMM_17_40

Rights and Permissions



How to cite this article:
Verghese VP. Introducing rubella vaccine into the national immunisation schedule. Indian J Med Microbiol 2017;35:143-5

How to cite this URL:
Verghese VP. Introducing rubella vaccine into the national immunisation schedule. Indian J Med Microbiol [serial online] 2017 [cited 2017 Mar 26];35:143-5. Available from: http://www.ijmm.org/text.asp?2017/35/1/143/202350




Dear Editor,

In a country such as India, with its vast population and inequalities in access to appropriate healthcare and amenities such as safe water, universal availability of vaccines has the potential to save lives and reduce childhood mortality and morbidity.

The Expanded Programme of Immunization in 1978 that provided primary vaccination against tuberculosis, diphtheria, pertussis, tetanus and typhoid was rechristened the Universal Immunization Programme (UIP) in 1985 with the addition of single-dose measles vaccine. No new vaccine was added to the programme for the next 16 years until the partial introduction of hepatitis B vaccine in 2002–2003. The past decade, however, has seen a much-needed increase in government-provided vaccines against several major killers of children, with the introduction of Japanese encephalitis (JE) vaccine in JE endemic districts from 2006 and the second dose of measles vaccine in 2010, scaling up of hepatitis B vaccination and introduction of Haemophilus influenzae type b (Hib) vaccine in 2011,[1] followed by introduction of inactivated polio vaccine in 2015 and rotavirus vaccine in 2016.

With almost 27 million children born each year, India accounts for one-fifth of child deaths worldwide. Although child deaths have halved since 1990[2] and the last case of wild poliovirus was reported in 2011,[1] India continues to have a significant proportion of under-immunised children. The Government of India's Mission Indradhanush, launched in December 2014 with the aim of improving and sustaining vaccine coverage to over 90% by 2020, has provided vaccines to 75.5 lakh children and 26.8 lakh pregnant women with the elimination of maternal and neonatal tetanus in 2015.[3]

The latest addition to the UIP is the measles-rubella (MR) vaccine slated for introduction in five states and union territories (Karnataka, Tamil Nadu, Pondicherry, Goa and Lakshadweep) in February 2017,[4] to be given to all children aged 9 months to 15 years before replacing measles vaccine administered in the immunisation schedule at 9–12 months and 16–23 months of age.

Measles has always been one of the more difficult diseases to control, from a public health perspective. It has the highest attack rate amongst vaccine-preventable diseases and is the single most common vaccine-preventable cause of death in children in India.[5] Mathematical modelling has estimated that the herd immunity required for interrupting wild virus measles transmission ranges from 94% to 98%.[6] Data from the National Family Health Survey indicate that measles vaccine coverage in children aged 12–23 months, although improved from the 58.8% documented in 2005–2006, is still <90% in most states in 2015–2016.[7] Inadequate vaccine coverage and the susceptibility of infants to wild measles virus in the community have prevented India from increasing the age of first dose of measles vaccine from 9 months to 1 year, with the disadvantage of lower seroprotection at the 9-month mark (80%–94%) compared to the over 95% seroprotection expected if given at or after 1 year of age.[8],[9] Added to this is the fact that studies outside Asia have suggested that initial immunisation at less than a year of age has a negative impact on antibody levels attained after a second dose of the vaccine.[10],[11],[12] All these factors probably contribute to the low measles vaccine efficacy documented in India that ranges from 66% to 84%.[13] This in turn has led to several outbreaks of measles in India [13],[14],[15] that often involve children younger than the recommended age for vaccination,[14] especially in areas with low vaccine coverage even within states with high overall coverage figures.

Rubella, although a more subclinical disease with less severe manifestations in those infected, leads to devastating consequences in the form of congenital rubella syndrome (CRS) in infants born to mothers infected with rubella, especially in the first trimester. The absence of a nationwide reporting system for CRS and lack of uniform testing have led to inadequate data on the population-based burden of disease. About 10%–15% of intrauterine infections are thought to be due to rubella, with various studies implicating CRS as the cause in 1%–60% of ocular abnormalities, 1.5%–29% of congenital deafness and about 30% of congenital heart disease.[16] Although there are no national estimates of women of childbearing age at risk, various serosurveys have documented susceptibility to rubella in significant proportions of young women. A study in Jammu on 11–18-year-old school girls showed that 33% lacked evidence of seroprotection against rubella.[17] Amongst 18–24 years old college students, seronegativity to rubella ranged from 12% in Mumbai [18] to 34% in girls in Pune.[19] Another serosurvey of medical and nursing students at Manipal University showed that 16.6% were susceptible to rubella, with 10.5% of those previously vaccinated having inadequate antibody levels.[20] Similar to measles, waning of antibodies against rubella has been documented in those vaccinated at younger ages,[21] and outbreaks of rubella are well documented,[15] emphasising the need for renewed opportunities for vaccination in older children and adolescents. A survey on employees at three eye hospitals in Tamil Nadu showed susceptibility to rubella ranging from 12% to 21%, with the highest proportion of susceptibles documented amongst married women.[22] Data from the National Institute of Communicable Diseases showed 12% overall susceptibility to rubella amongst pregnant women in Delhi from 1988 to 2002[23] while another study documented 31% susceptibility amongst women in Amritsar in 2004.[24] Susceptibility to rubella was also shown to be higher in rural areas, attributed to lower population density, in two studies both of which showed more susceptibility to rubella in women from a higher socioeconomic class.[24],[25] Pregnant women with bad obstetric history were also shown to have evidence of recent infection, with rubella IgM positivity ranging from over 50% in those with intrauterine deaths, stillbirth and premature delivery to 17%–20% in those with abortions and recurrent abortions.[26]

Control of both rubella and measles rests on maintaining high and sustained vaccination coverage. Unlike Hib vaccination where even partial coverage within a community leads to a reduction of disease due to the herd effect,[27] single-dose rubella vaccine in young children combined with low rubella vaccination coverage has been shown to shift the age of incidence of rubella towards adolescents and young adults and lead to outbreaks of CRS.[28] In this context, the Government of India's decision to give MR vaccine to all children from 9 months to 15 years of age will help to prevent the shift of rubella towards adolescents and women of childbearing age. Similarly, measles vaccination coverage has to remain high to reduce the pool of susceptibles in the population who are at risk for acquisition of wild measles virus infection. The Government's strategy for measles control in India has been to use the established field surveillance network and personnel from the successful polio eradication campaign to detect and report measles outbreaks and to administer second doses of measles vaccine, as well as for catch-up vaccination in areas with low vaccine coverage.[29] In addition to immunisation, continued surveillance as well as monitoring and intervention for adverse events and programmatic errors is essential for sustained rubella and measles vaccination coverage over time. Elimination of measles and control of rubella by 2020 will necessitate the rapid provision of MR vaccine to other states in the country, as well as another opportunity in future for older children and adolescents to receive measles- and rubella-containing vaccines in the national programme.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 ~ References Top

1.
Lahariya C. A brief history of vaccines & vaccination in India. Indian J Med Res 2014;139:491-511.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
GAVI 2015. Alliance Partnership Strategy with India, 2016-2021. Report to the Board; 2-3 December, 2015. Available from: http://www.gavi.org/about/governance/gavi-board/minutes/2015/2-dec/. [Last cited on 2017 Jan 16].  Back to cited text no. 2
    
3.
Background: Routine Immunization. National Health Mission, Ministry of Health and Family Welfare, Government of India. Available from: http://www.nrhm.gov.in/nrhm-components/rmnch-a/immunization/background.html. [Last cited on 2017 Jan 16].  Back to cited text no. 3
    
4.
Ghosh A. Measles-Rubella Vaccine to Roll Out in February. The Indian Express; 10 January, 2017. Available from: http://www.indianexpress.com/article/india/measles-rubella-vaccine-to-roll-out-in-february-4467248/. [Last cited on 2017 Jan 16].  Back to cited text no. 4
    
5.
Steinhoff MC, John TJ. Appropriate strategy for immunization of children in India. IV: Measles and its control, priority number one. Indian J Pediatr 1982;49:303-10.  Back to cited text no. 5
    
6.
Hethcote HW. Measles and rubella in the United States. Am J Epidemiol 1983;117:2-13.  Back to cited text no. 6
    
7.
National Family Health Survey India. Fact Sheets. Available from: http://www.rchiips.org/nfhs/factsheet_NFHS-4.shtml. [Last cited on 2017 Jan 16].  Back to cited text no. 7
    
8.
Job JS, John TJ, Joseph A. Antibody response to measles immunization in India. Bull World Health Organ 1984;62:737-41.  Back to cited text no. 8
    
9.
Singh R, John TJ, Cherian T, Raghupathy P. Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age. Indian J Med Res 1994;100:155-9.  Back to cited text no. 9
    
10.
Wilkins J, Wehrle PF. Additional evidence against measles vaccine administration to infants less than 12 months of age: Altered immune response following active/passive immunization. J Pediatr 1979;94:865-9.  Back to cited text no. 10
    
11.
Stetler HL, Orenstein WA, Bernier RH, Herrmann KL, Sirotkin B, Hopfensperger D, et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Paediatrics 1986;77:471-6.  Back to cited text no. 11
    
12.
Isik N, Uzel N, Gökçay G, Kiliç A, Yilmaz G, Sadikoglu B, et al. Seroconversion after measles vaccination at nine and fifteen months of age. Pediatr Infect Dis J 2003;22:691-5.  Back to cited text no. 12
    
13.
Murhekar MV, Hutin YJ, Ramakrishnan R, Ramachandran V, Biswas AK, Das PK, et al. The heterogeneity of measles epidemiology in India: Implications for improving control measures. J Infect Dis 2011;204 Suppl 1:S421-6.  Back to cited text no. 13
    
14.
Nujum ZT, Varghese S. Investigation of an outbreak of measles: Failure to vaccinate or vaccine failure in a community of predominantly fishermen in Kerala. J Infect Public Health 2015;8:11-9.  Back to cited text no. 14
    
15.
Vaidya SR, Kamble MB, Chowdhury DT, Kumbhar NS. Measles & rubella outbreaks in Maharashtra state, India. Indian J Med Res 2016;143:227-31.  Back to cited text no. 15
[PUBMED]  [Full text]  
16.
Dewan P, Gupta P. Burden of congenital rubella syndrome (CRS) in India: A systematic review. Indian Pediatr 2012;49:377-99.  Back to cited text no. 16
    
17.
Sharma H, Chowdhari S, Raina TR, Bhardwaj S, Namjoshi G, Parekh S. Sero-surveillance to assess immunity to rubella and assessment of immunogenicity and safety of a single dose of rubella vaccine in school girls. Indian J Community Med 2010;35:134-7.  Back to cited text no. 17
[PUBMED]  [Full text]  
18.
Gohil DJ, Kothari ST, Chaudhari AB, Gunale BK, Kulkarni PS, Deshmukh RA, et al. Seroprevalence of measles, mumps, and rubella antibodies in college students in Mumbai, India. Viral Immunol 2016;29:159-63.  Back to cited text no. 18
    
19.
Phalgune DS, Yervadekar RC, Sharma HJ, Dhere RM, Parekh SS, Chandak AO, et al. Sero-surveillance to assess rubella susceptibility and assessment of immunogenicity and reactogenicity of rubella vaccine in Indian girls aged 18-24 years. Hum Vaccin Immunother 2014;10:2813-8.  Back to cited text no. 19
    
20.
Arunkumar G, Vandana KE, Sathiakumar N. Prevalence of measles, mumps, rubella, and varicella susceptibility among health science students in a university in India. Am J Ind Med 2013;56:58-64.  Back to cited text no. 20
    
21.
Boulianne N, De Serres G, Ratnam S, Ward BJ, Joly JR, Duval B. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: Effect of vaccine type and age at vaccination. Vaccine 1995;13:1611-6.  Back to cited text no. 21
    
22.
Vijayalakshmi P, Anuradha R, Prakash K, Narendran K, Ravindran M, Prajna L, et al. Rubella serosurveys at three Aravind eye hospitals in Tamil Nadu, India. Bull World Health Organ 2004;82:259-64.  Back to cited text no. 22
    
23.
Gandhoke I, Aggarwal R, Lal S, Khare S. Seroprevalence and incidence of rubella in and around Delhi (1988-2002). Indian J Med Microbiol 2005;23:164-7.  Back to cited text no. 23
[PUBMED]  [Full text]  
24.
Singla N, Jindal N, Aggarwal A. The seroepidemiology of rubella in Amritsar (Punjab). Indian J Med Microbiol 2004;22:61-3.  Back to cited text no. 24
[PUBMED]  [Full text]  
25.
Yadav S, Gupta S, Kumari S. Seroprevalence of rubella in women of reproductive age. Indian J Pathol Microbiol 1995;38:139-42.  Back to cited text no. 25
[PUBMED]  [Full text]  
26.
Fomda BA, Thokar MA, Farooq U, Sheikh A. Seroprevalence of rubella in pregnant women in Kashmir. Indian J Pathol Microbiol 2004;47:435-7.  Back to cited text no. 26
    
27.
Verghese VP, Friberg IK, Cherian T, Raghupathy P, Balaji V, Lalitha MK, et al. Community effect of Haemophilus influenzae type b vaccination in India. Pediatr Infect Dis J 2009;28:738-40.  Back to cited text no. 27
    
28.
Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: Retrospective survey and systematic review. BMJ 1999;319:1462-7.  Back to cited text no. 28
    
29.
World Health Organization. Improving Measles Control in India. Available from: http://www.who.int/features/2013/india_measles/en/. [Last cited on 2017 Jan 19].  Back to cited text no. 29
    




 

Top
Print this article  Email this article
 

    

2004 - Indian Journal of Medical Microbiology
Published by Wolters Kluwer - Medknow

Online since April 2001, new site since 1st August '04